Vysali Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 5.43 Cr
- Company Age 45 Year, 3 Months
- Last Filing with ROC 14 Dec 2018
- Revenue Growth 24.54%
- Profit Growth 27.44%
- Ebitda 71.82%
- Net Worth -15.33%
- Total Assets -1.79%
About Vysali Pharmaceuticals
Vysali Pharmaceuticals Ltd (VPL) is a Public Limited Indian Non-Government Company incorporated in India on 29 October 1979 and has a history of 45 years and three months. Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 14 December 2018. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 5.43 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24231KL1979PLC003112
- Company No.
003112
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
29 Oct 1979
- Date of AGM
28 Sep 2018
- Date of Balance Sheet
14 Dec 2018
- Listing Status
Listed
- ROC Code
Roc-Ernakulam
Industry
What products or services does Vysali Pharmaceuticals Ltd offer?
Vysali Pharmaceuticals Ltd offers a wide range of products and services, including Pharmacy Dropshipper, Online Pharmacy.
Who are the key members and board of directors at Vysali Pharmaceuticals?
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Vysali Pharmaceuticals.
Vysali Pharmaceuticals Ltd, for the financial year ended 2016, experienced significant growth in revenue, with a 24.54% increase. The company also saw a substantial improvement in profitability, with a 27.44% increase in profit. The company's net worth observed a substantial decline by a decrease of 15.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vysali Pharmaceuticals?
In 2017, Vysali Pharmaceuticals had a promoter holding of 10.54% and a public holding of 89.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vysali Pharmaceuticals?
Unlock and access historical data on people associated with Vysali Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vysali Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vysali Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.